Dyslipidemia and Oxidative Stress in PCOS
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is a common metabolic and reproductive disorder in women. An increased cardiovascular risk has to be anticipated in PCOS as it is a metabolically unstable condition. Among cardiovascular risk factors, dyslipidemia is certainly the most persistent and highly prevalent. Predominant observation is an elevation of LDL cholesterol in all PCOS patients. Decreased concentrations of HDL cholesterol are found in obese PCOS from the third decade of life onwards while triglycerides start to rise from the second decade of life. PCOS is associated with oxidative stress, namely increased production of free radicals followed by decreased serum antioxidant levels and antioxidant enzyme activity. Broad range of endocrine and metabolic disturbances like obesity, hyperinsulinemia as well as dyslipidemia might be responsible for PCOS-associated oxidative stress. Therapeutic interventions in PCOS women based on lifestyle modification as well as use of insulin sensitizers did not show significant effect on dyslipidemia. Statins are considered to be a group of promising agents that are safe and effective in improving total cholesterol, LDL cholesterol and triglycerides, and possess antioxidant activity. Supplementation with omega-3 fatty acids, α-lipoic acid and N-acetylcysteine is considered to have an anti-inflammatory and antioxidant effect and to improve dyslipidemia and insulin sensitivity in PCOS women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome
Legro, R. S., Kunselman, A. R., & Dunaif, A. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00948-2 · Cited by 622
The Molecular Basis for Oxidative Stress-Induced Insulin Resistance
Evans, J. L., Maddux, B. A., & Goldfine, I. D. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.1040 · Cited by 587
Hoeger, K., Davidson, K., Kochman, L., Cherry, T., Kopin, L., & Guzick, D. S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0461 · Cited by 256
Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome
Berneis, K., Rizzo, M., Hersberger, M., Rini, G. B., Di Fede, G., Pepe, I., Spinas, G. A., & Carmina, E. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01897.x · Cited by 94
Cited by
The pathogenesis and treatment of polycystic ovary syndrome: What’s new?
Bednarska, S., & Siejka, A. (2017) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/59380 · Cited by 284
Insulin and the polycystic ovary syndrome
Macut, D., Bjekić-Macut, J., Rahelić, D., & Doknić, M. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.06.011 · Cited by 261
Self-citationCardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome
Glintborg, D., Rubin, K. H., Nybo, M., Abrahamsen, B., & Andersen, M. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0680-5 · Cited by 200
“Previous studies estimated that 70% women with PCOS had borderline or high lipid levels [27], but dyslipidemia Table 3 Characteristics according to development of CVD in PCOS Denmark and controls”
BackgroundNational lipid association annual summary of clinical lipidology 2016
Bays, H. E., Jones, P. H., Orringer, C. E., Brown, W. V., & Jacobson, T. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.002 · Cited by 128
Tefagh, G., Payab, M., Qorbani, M., Sharifi, F., Sharifi, Y., Ebrahimnegad Shirvani, M. S., Pourghazi, F., Atlasi, R., Shadman, Z., Rezaei, N., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09082-3 · Cited by 102
Metadata
- Authors
- Macut, D., Bjekić-Macut, J., & Savić-Radojević, A.
- Venue
- Frontiers of Hormone Research
- Publisher
- S. Karger AG
- Published
- 2012-10-18
- Volume
- 40
- Pages
- 51-63
- ISSN
- 0301-3073 (ISSN-L)
- 1662-3762
- OpenAlex
- W1578150740
- Cited by
- 139
- References
- 4
- FWCI
- 17.86
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.